The burden of pneumococcal disease among adults in developed countries is neither widely
known nor appreciated. The incidence of pneumococcal pneumonia is uncertain because a …

Use of the pneumococcal conjugate vaccines among children in the US since 2000 has
dramatically reduced pneumococcal disease burden among adults. Significant vaccine …

To overview the present global burden of pneumococcal disease is important because new
preventive measures such as the pneumococcal conjugate vaccine 13 are currently being …

This chapter focuses on the epidemiology of pneumococcal disease in terms of pathogen
characteristics and host risk factors. The clinical manifestations of Streptococcus …

In many countries of the developing world, pneumonia remains a leading cause of morbidity
and premature mortality. In their quest for effective control measures not dependent on the …

OBJECTIVES: To summarize published data on the clinical and economic burden,
epidemiology, antimicrobial resistance levels, serotype prevalence, and prevention …

Introduction Streptococcus pneumoniae is a major cause of morbidity and mortality. We
sought to describe the epidemiology of non-invasive and invasive pneumococcal disease in …

Introduction Pneumococcal disease (PD) significantly contributes to morbidity and mortality,
carrying substantial economic and public health burden. This article is a targeted review of …

Ten prospective clinical trials conducted in elderly and high-risk adults have failed to show
that pneumococcal vaccine prevents pneumococcal bacteraemia and all pneumonia …

Pneumococcal vaccination : Current Opinion in Infectious Diseases Pneumococcal vaccination
: Current Opinion in Infectious Diseases Log in or Register Subscribe to journalSubscribe Get …